Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

In the cancer population, vitamin D deficiency was associated with higher odds of infection only among Black participants (aOR 3.50; 95%CI 1.22 to 10.01); no other associations were observed.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Multiple reported designs.

Multiple reported designs

More than one design is explicitly reported; examine the supporting methods.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We performed a nested case-control study within the UK biobank cohort, among all individuals with at least one serum VitD level measurement at baseline (2006−2010) and a COVID-19 polymerase chain reaction (PCR) results recorded, and individuals with previous cancer diagnosis.

Source: Abstract.

Our study population consisted of participants enrolled in the UK Biobank, a prospective cohort study comprising of approximately 500,000 participants aged 40 to 69 years, registered with the UK National Health Service (NHS), at the time of their initial assessment.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank

Multiple reported designs · PLOS One · 2025

Original publication title

Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank

Maria J. Monroy-Iglesias; Rathesh Thavarajah; Kerri Beckmann; Debra H. Josephs; Sheeba Irshad; Sophia N. Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla

© 2025 Monroy-Iglesias et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Low VitD levels were associated with an increased risk of COVID-19 hospitalisation but showed only a weak association with infection risk. Black and Asian populations had higher infection risk associated with VitD deficiency, but this did not translate to increased hospitalisation. In contrast, White populations with low VitD levels exhibited a higher risk of hospitalisation. There was no evidence of an interaction between VitD levels and ethnicity affecting infection or hospitalisation risk. In the cancer cohort, no significant associations were observed for COVID-19 infection or hospitalisation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Vitamin D (VitD) plays an important role in immune modulation. VitD deficiency is associated with increased susceptibility to acute respiratory syndrome as observed in COVID-19. We evaluated potential associations between serum VitD levels and risk of COVID-19 infection and hospitalisation, within the overall and cancer populations.

Source: Background

Abstract: What methods does the paper describe?

We performed a nested case-control study within the UK biobank cohort, among all individuals with at least one serum VitD level measurement at baseline (2006−2010) and a COVID-19 polymerase chain reaction (PCR) results recorded, and individuals with previous cancer diagnosis. Binary multivariable logistic regression was performed to assess associations between VitD levels and risk of COVID-19 infection (positive PCR), and hospitalisation (COVID-19-positive PCR in hospital), and stratified by ethnicity.

Source: Methods

Abstract: Results

Of 151,543 participants, 21,396 tested positive for COVID-19. Of 24,400 individuals with cancer, 2,608 tested positive. In the total cohort, VitD insufficiency (Adjusted Odds Ratio (aOR) 0.97, 95% Confidence Interval (CI) 0.94 to 1.00) and deficiency (aOR 0.95, 95%CI 0.90 to 0.99) were associated with slightly lower odds of COVID-19 infection. In contrast, both VitD insufficiency (aOR 1.19, 95%CI 1.08 to 1.31) and deficiency (aOR 1.36, 95%CI 1.19 to 1.56) were associated with higher odds of COVID-19 hospitalisation. Among Asian (aOR 1.50; 95%CI 1.08 to 2.07) and Black (aOR 1.57; 95%CI 1.14 to 2.16) participants, VitD deficiency was associated with higher odds of COVID-19 infection.

Among White participants, VitD insufficiency was associated with slightly lower odds of COVID-19 infection (aOR 0.97; 95%CI 0.86 to 0.95), while both VitD insufficiency (aOR 1.19; 95%CI 1.08 to 1.32) and deficiency (aOR 1.44; 95%CI 1.25 to 1.66) were associated with increased odds of hospitalisation. In the cancer population, vitamin D deficiency was associated with higher odds of infection only among Black participants (aOR 3.50; 95%CI 1.22 to 10.01); no other associations were observed.

Source: Results

Abstract: Conclusions

Low VitD levels were associated with an increased risk of COVID-19 hospitalisation but showed only a weak association with infection risk. Black and Asian populations had higher infection risk associated with VitD deficiency, but this did not translate to increased hospitalisation. In contrast, White populations with low VitD levels exhibited a higher risk of hospitalisation. There was no evidence of an interaction between VitD levels and ethnicity affecting infection or hospitalisation risk. In the cancer cohort, no significant associations were observed for COVID-19 infection or hospitalisation.

Source: Conclusions
Authors’ abstract

Background

Vitamin D (VitD) plays an important role in immune modulation. VitD deficiency is associated with increased susceptibility to acute respiratory syndrome as observed in COVID-19. We evaluated potential associations between serum VitD levels and risk of COVID-19 infection and hospitalisation, within the overall and cancer populations.

Methods

We performed a nested case-control study within the UK biobank cohort, among all individuals with at least one serum VitD level measurement at baseline (2006−2010) and a COVID-19 polymerase chain reaction (PCR) results recorded, and individuals with previous cancer diagnosis. Binary multivariable logistic regression was performed to assess associations between VitD levels and risk of COVID-19 infection (positive PCR), and hospitalisation (COVID-19-positive PCR in hospital), and stratified by ethnicity.

Results

Of 151,543 participants, 21,396 tested positive for COVID-19. Of 24,400 individuals with cancer, 2,608 tested positive. In the total cohort, VitD insufficiency (Adjusted Odds Ratio (aOR) 0.97, 95% Confidence Interval (CI) 0.94 to 1.00) and deficiency (aOR 0.95, 95%CI 0.90 to 0.99) were associated with slightly lower odds of COVID-19 infection. In contrast, both VitD insufficiency (aOR 1.19, 95%CI 1.08 to 1.31) and deficiency (aOR 1.36, 95%CI 1.19 to 1.56) were associated with higher odds of COVID-19 hospitalisation. Among Asian (aOR 1.50; 95%CI 1.08 to 2.07) and Black (aOR 1.57; 95%CI 1.14 to 2.16) participants, VitD deficiency was associated with higher odds of COVID-19 infection.

Among White participants, VitD insufficiency was associated with slightly lower odds of COVID-19 infection (aOR 0.97; 95%CI 0.86 to 0.95), while both VitD insufficiency (aOR 1.19; 95%CI 1.08 to 1.32) and deficiency (aOR 1.44; 95%CI 1.25 to 1.66) were associated with increased odds of hospitalisation. In the cancer population, vitamin D deficiency was associated with higher odds of infection only among Black participants (aOR 3.50; 95%CI 1.22 to 10.01); no other associations were observed.

Conclusions

Low VitD levels were associated with an increased risk of COVID-19 hospitalisation but showed only a weak association with infection risk. Black and Asian populations had higher infection risk associated with VitD deficiency, but this did not translate to increased hospitalisation. In contrast, White populations with low VitD levels exhibited a higher risk of hospitalisation. There was no evidence of an interaction between VitD levels and ethnicity affecting infection or hospitalisation risk. In the cancer cohort, no significant associations were observed for COVID-19 infection or hospitalisation.

Publication and source details

Original title: Effects of vitamin D on COVID-19 risk and hospitalisation in the UK biobank

Maria J. Monroy-Iglesias; Rathesh Thavarajah; Kerri Beckmann; Debra H. Josephs; Sheeba Irshad; Sophia N. Karagiannis; Mieke Van Hemelrijck; Aida Santaolalla

PLOS One · 2025

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: maria.j.monroy_iglesias@kcl.ac.uk
© 2025 Monroy-Iglesias et al2025Monroy-Iglesias et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.The author(s) received no specific funding for this work.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:25:21.231663+00:00

DOI: 10.1371/journal.pone.0328232 · PMC12273939